SEC Form 4 · accession 0001209191-17-026899

NEUROCRINE BIOSCIENCES INC · NBIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 12, 2017

Accepted (ET)

Apr 13, 2017 · 5:32 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000914475

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 12, 2017	M	20,000	$3.40	A	57,354	D
Common Stock^F1	Apr 12, 2017	F	1,312	$51.80	D	56,042	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option	$3.40	Apr 12, 2017	M	20,000	D	Jun 25, 2010	May 25, 2017	Common Stock	20,000	0	D

F1The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the April 12, 2017 market close price ($51.80), and this net amount ($48.40) was then multiplied by the number of options (20,000), with the resulting amount then divided by the market close price to result in a net issuance of 18,688 shares to the optionee. The 1,312 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.